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Historic events have occurred in the last decade in the bat-
tle against malaria, one of humanity’s most ancient and
deadly enemies. In 2000, 189 nations, under the United
Nations Development Programme [1], deﬁned malaria con-
trol as one of the Millennium Development Goals, with a
target of reducing malaria cases and deaths by 50% in 2010
and by 75% in 2015. This issue’s themed section is devoted
to the ongoing efforts to control malaria, comprising vector
control, surveillance, the development and distribution of
drugs that are highly effective against malaria, intermittent
preventive treatment, improved diagnosis, targeted case
management, and vaccine development [2–5]. These efforts
have resulted in impressive achievements, mainly in sub-
Saharan Africa that incurs the brunt of malaria-related child
mortality. Bed-net coverage increased from approximately
5% in 2000 to more than 45% in 2010 in sub-Saharan Africa
(Fig. 1). There was an estimated global reduction in deaths
from malaria of 20%, from approximately 985 000 in 2000 to
781 000 in 2009 (data for sub-Saharan Africa are shown in
Fig. 1). This is especially impressive considering that, in the
previous decade, mortality had been increasing, because of
chloroquine resistance. Although, in absolute numbers, the
reductions are largest in sub-Saharan Africa, the relative
reduction is most prominent in settings of low and moderate
endemicity. Ultimately, the battle will be decided in those
areas with the most intense transmission of malaria.
However, a recently published study presents worrying
ﬁndings: the recrudescence of malaria attacks within
30 months of the introduction of long-lasting insecticide
(deltamethrin)-treated nets (LLINs) in an area of intense,
perennial malaria transmission [7]. The study was conducted
in Dielmo, a small village in the Sudan-savannah region of
central Senegal, between 2007 and 2010, and included 405
participants at the start and 465 at the end. LLINs (Permanet
2.0) were introduced in July 2008. Throughout the study
period, uncomplicated malaria was treated with the artesimin
combination therapy artesunate–amodaquine, and no thera-
peutic failures were noted. The incidence of malaria
decreased from 5.45 malaria attacks per 100 person-months
in the 18 months before introduction of LLINs to 0.41 in the
24 months thereafter (incidence rate ratio adjusted for age
and seasonality, 0.07 (95% CI 0.05–0.10)). However, the inci-
dence increased back to 4.57 per 100 person-months in the
following 4 months (up to December 2010), and the adjusted
incidence rate ratio for this period, as compared with the
baseline before the introduction of LLINs, was not signiﬁcant
(0.84 (95% CI 0.59–1.21)).
Three explanations were given for the observed ﬁndings.
The most important was pyrethroid resistance. The fre-
quency of the kdr west allele (a mutation in the para-sodium
channel gene of Anopheles gambiae conferring resistance to
pyrethroids) increased from 8% in 2007 to 48% in 2010, and
37% of A. gambiae mosquitoes were resistant to deltamethrin
in 2010. Second, the largest increase in malaria incidence
occurred in participants >10 years of age. In this group, the
incidence of malaria in the last 4 months of the study
was higher than at baseline 3 years previously, which is com-
patible with the theory of decreased protective immunity
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FIG. 1. Bed-net coverage (left axis) and incidence of new malaria cases and death (right axis) in sub-Saharan Africa. Data obtained from the
yearly Millennium Development Goals Report [18].
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following effective transmission interruption in infancy and
early childhood. Finally, a slight shift was observed in mos-
quito biting times. In 2007 and 2008, the peak biting time
was between 2 and 3 a.m., but in 2009 and 2010 the peak
occurred between midnight and 2 a.m. Bed-net ownership,
use and maintenance were high throughout the study,
although there was a decreasing trend throughout the study
period.
Previous studies have also examined the sustainability of
malaria control interventions over time and the hypothesis
of an age shift related to delayed immunity acquisition [8–
16]. The results of these and the current study are shown in
Table 1. In most, the beneﬁt initially afforded by insecticide-
treated bed-nets and other malaria control interventions
(e.g. effective treatment and indoor residual spraying) was
maintained throughout study periods of 2–9 years after
introduction of the control measure. A rebound in mortality
was noted in a trial in Burkina Faso, especially after 6 years
of exposure to bed-nets, although to lower levels than base-
line [9]. In The Gambia, a rebound in parasitaemia was noted
in two of ten nationwide study sites, but parasitaemia
returned to the low levels achieved with the intervention at
longer follow-up [12]. A shift towards a higher age among
those admitted for malaria was noted only in The Gambia
[13]. Notably, most previous studies limited the age range
assessed to children aged <5 years (the target of most inter-
ventions), whereas Trape et al. showed an increased inci-
dence of malaria in children aged >10 years and adults [7].
LLINs were assessed only in this last study. Bed-net usage
decreased with time in two of the three studies showing
increased event rates [7,9], compliance was not assessed in
one [12], and others documented stable or increased usage
(Table 1). Methods of surveillance and the outcomes exam-
ined in the studies were different. The study of Trape et al.
accounted for every individual in a small study region
throughout the study period, and included daily active assess-
ment of all febrile episodes and entomological indices. Most
other studies assessed mortality or other broader measures
of effectiveness, but were conducted on much larger popula-
tions than the current study.
The scenario presented by Trape et al. might defeat the
immense efforts that have been invested in the last decade in
malaria control. The results call into question many attempts
to model the transmission and epidemiology of malaria [17].
Models have incorporated climate, vegetation, other environ-
mental factors, interactions between human immunodeﬁ-
ciency virus and malaria, vaccine introduction, drug efﬁcacy,
economic support, and other factors. However, one can
hardly predict the behavioural response of mosquitoes to
people sleeping under bed-nets. Our understanding of the
timeline of the development of resistance to insecticides (in
mosquitoes) and to antimalarial drugs (in the malaria para-
site) is insufﬁcient. The results of the current study stand lar-
gely in contrast to those of previous, larger studies, which
showed stable and durable beneﬁts of bed-nets and other
malaria control interventions. Longer follow-up might show
this to be a temporal ﬂuctuation. The starting point of 8%
resistance to pyrethroids might have been favourable for a
rapid increase in further resistance acquisition. In any case,
the results of this study emphasize the need for surveillance
of malaria to detect such events early and enable appropriate
intervention.
Randomized controlled trials have shown the efﬁcacy of
insecticide-treated bed-nets [18]. However, their effective-
ness in large-scale programme conditions over longer peri-
ods of time and long-term compliance in a situation of
declining malaria incidence must be monitored. Intensive
surveillance such as that conducted in the study in Dielmo
[7] is obviously not feasible in large populations. National
cross-sectional data are uninformative, because the preva-
lence of malaria is heterogeneous in different locations and
seasons. However, small-scale intensive surveys coupled
with the acquisition of cross-sectional data should be
encouraged. Funding for malaria control at this time should
take into consideration the increasing need for appropriate
surveillance.
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